Business
Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
Revenues hold steady from prior quarter ended June 30, 2021 Net loss of $100,000, or $(0.04) per share for the second quarter compared to a net loss of $1.1
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nRevenues hold steady from prior quarter ended June 30, 2021\n\n\nNet loss of $100,000, or $(0.04) per share for the second quarter compared to a net loss of $1.1 million or $(0.52) per share for the prior quarter ended June 30, 2021\n\n\nBreak-even EBITDAS for the quarter versus EBITDAS loss of $800,000 for the prior quarter ended June 30, 2021\n\n\n$8.4 million of cash and strengthened balance sheet\n\n\n WOODSTOCK, Ga.--(BUSINESS WIRE)--\nSonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2021.\n\n“This quarter we focused on our new product launches as well as strengthening our results of operations and balance sheet,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. “We are pleased to see the hard work reflected in improving financial results. Although, we continue to transition away from unprofitable revenues generated by an in-house dermatology sales force and our Latin America partner Invekra, we opened up new, higher margin revenue streams with our OTC sales, expanded partnerships and new product introductions. We also raised funds we intend to deploy commercializing new products and entering new markets.”\n\nBusiness Highlights for the Second Fiscal Quarter\n\nSonoma continues to expand the reach of its products through partners and its own commercialization:\n\nIn August, Sonoma launched two new dental products. OroGenix Oral Hygiene Rinse, developed with its partner Gabriel Science, LLC, is Sonoma’s second dental product in the U.S. In Switzerland, Sonoma and its partner, Medical Systems Solutions launched Microdacyn® Oral Care for both professional and consumer use.\n\nOn September 28, 2021, Sonoma launched its OTC products, Regenacyn® Advanced Scar Gel and Ocucyn® Eyelid & Eyelash Cleanser, on Amazon.com in the U.S., and MucoClyns™ on Amazon sites in Europe. All three products are based on Sonoma’s patented Microcyn® technology and are immediately available for customer orders.\n\nAlso on September 28, 2021, Sonoma launched Regenacyn® Plus, a prescription-strength scar gel which is available as an office-dispen...